Heron Therapeutics | HRTX - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
ALKERMES USD 1.86B 56.17M 2026-09
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 637.11M 39.9M 2026-09
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Emergent BioSolutions USD 555.9M 242.7M 2023-06
GlaxoSmithKline GBP 6.03B 227M 2026-09
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 606.26M 79.46M 2026-09
Ligand Pharmaceuticals USD 94.5M 39.4M 2026-09
Merck USD 10.75B 5.02B 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 1.18B 995.96M 2026-09
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Veracyte USD 133.73M 7.37M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09